イーライリリーとCSL、クラザキズマブ抗体開発で提携
Thursday, March 12, 2026
2 min read
正規ソースAustralia
Summary Only30%
変更点
Eli Lilly and CSL have partnered to jointly develop clazakizumab, an anti-interleukin-6 monoclonal antibody, through a strategic licensing agreement.
Source Report
CSL and Eli Lilly have entered into a strategic licensing agreement for the development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody.
Sigvera Intelligence
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
110 業界シグナルPartnership
Company Activityすべて見る
Source Verification
Verified from official source
Publisher—
公開日Mar 12, 2026
ソース分類Verified Canonical
シグナルタイムライン
初回報道Mar 12, 2026
インデックスMar 12, 2026
公開Mar 12, 2026
https://www.pharmtech.com/view/lilly-and-csl-partner-on-clazakizumab-antibody-development
Read Full Source信頼度:80%
Get cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
ログイン